New format simplifies administration for clinicians
News
EpilepsyGTx and Viralgen partner to scale AAV manufacturing for EPY201
Collaboration supports first‑in‑human gene therapy trial preparation
Zerion partner files first EU application for Dispersome‑enabled product
Submission marks major milestone for novel excipient BLG
Tozorakimab shows broad COPD benefit in new phase 3 data
Trials suggest meaningful reductions in exacerbations
Study highlights advance in influenza protection for older adults
Phase 3 data supports combined vaccine technologies
NICE backs daratumumab quadruplet for transplant‑eligible myeloma
Guidance supports MRD‑guided treatment approach
Teitur reports positive early data for Parkinson’s peptide TT‑P34
Phase 1 trial shows strong safety and CNS exposure
Amivantamab regimen delivers longest survival in EGFR Ex20ins lung cancer
New data shows nearly three‑year median overall survival
NICE backs ibrutinib regimen for untreated mantle cell lymphoma
Guidance offers first alternative to transplant‑based first‑line care
Livdelzi accepted in Scotland for treatment of PBC
SMC decision expands options for people with chronic itch
FDA approves Tivicay pd for youngest HIV patients
New treatment option expands paediatric HIV care access
Koala trial doses first patient with novel KMA‑targeting CAR‑T
Australian teams advance first‑in‑human multiple myeloma therapy
Heparegenix wins orphan drug status for darizmetinib
Designation supports development for post‑hepatectomy liver failure
IMAVVY approved as first targeted therapy for wAIHA
New treatment reduces pathogenic IgG while preserving B‑cell function
Nxera partner gains acceptance for NBI‑1117567
Phase 2 study to assess muscarinic M1 agonist in Alzheimer’s cognition
